PharmaTelevision - London Genetics: Bridging the Gap

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: London Genetics: Bridging the Gap

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this exclusive interview, Fintan Walton talks to Professor Nick Lench, CEO of London Genetics, about the company’s vision to facilitate access for biotech and pharmaceutical companies to the wealth of genetic information and expertise at a number of London’s leading academic institutes. Nick discusses the company’s overall strategy, the services that it is providing and the benefits that a single point of access brings to London’s genetics community.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

London Genetics's role and purposes.

Fintan Walton:

Hello and welcome to PharmaVentures Business Review face to face here in London. On this show I have Nick Lench, CEO of London Genetics, welcome to the show.

Nick Lench:

Thank you.

Fintan Walton:

Nick, London Genetics is an organization that's been set up relatively recently you are obviously the CEO of that organization could you tell us what London Genetics is all about and how it came about?

Nick Lench:

Yes. We are a new company we are formed in April of this year and we bring together London's leading research institutions. So our partners have signed up to the company it's the first time that these institutions have come together to collaborate in the field of genetics. So we have seven partners they are Imperial College, University College, King's College, Queen Mary, St. George's, The Institute of Cancer Research and the London School of Hygiene & Tropical Medicine.

Fintan Walton:

That's amazing to pull so many people together into one organization that's a, feat in itself, so now that the organization is set up what is it's purpose, what are you what's the role of London Genetics?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Nick Lench

CEO

Nick Lench has extensive experience of knowledge and technology transfer, genetics research in academia and industry, research strategy development, intellectual property management, partnering and licensing. Before joining London Genetics, he was Professor of Medical Genetics at Cardiff University and Director of the Wales Gene Park. Between 1999 and 2003, Nick was Programme Director for Inflammation Biology and Discovery Genetics at Oxagen.

London Genetics Limited

London Genetics Limited is a commercial company created to facilitate and manage partnerships between the healthcare industry and London centres of excellence in genetics and genomics-based medical research. It uses a multicentre approach through a consortium of leading London research institutions that includes: Imperial College London, The Institute of Cancer Research, King's College London, The London School of Hygiene & Tropical Medicine, Queen Mary, University of London, St. George's, University of London and University College London. The company is funded by the London Development Agency.